Effects of bilateral sequential theta-burst stimulation on 5-HT_{1A} receptors on dorsolateral prefrontal cortex in treatment resistant depression

Matej Murgaš^{1*}, Jakob Unterholzner^{1*}, Peter Stöhrmann¹, Cécile Philippe²,
Godber M. Godbersen¹, Lukas Nics², Murray B. Reed¹, Chrysoula Vraka², Thomas Vanicek¹,
Wolfgang Wadsak², Georg S. Kranz^{1,4}, Andreas Hahn¹, Markus Mitterhauser^{2,3,5},
Marcus Hacker², Siegfried Kasper^{1#}, Rupert Lanzenberger^{1#}, Pia Baldinger-Melich¹

(* contributed equally)

¹Department of Psychiatry and Psychotherapy, Clinical Division of General Psychiatry,
Medical University of Vienna, Austria

²Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine,
Medical University of Vienna, Austria

³Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria

⁴Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong

⁵Department of Chemistry, Institute of Inorganic Chemistry, University of Vienna, Austria

Main article		
Word count	203	Abstract
	4089	Main section
2 tables/1 figure, 1suppl. table, 93 references		

Correspondence to:

Univ. Prof. Rupert Lanzenberger, MD, PD
Department of Psychiatry and Psychotherapy
Medical University of Vienna
Währinger Gürtel 18-20, 1090 Vienna, Austria
rupert.lanzenberger@meduniwien.ac.at
<http://www.meduniwien.ac.at/neuroimaging/>

Em.Univ. Prof. Siegfried Kasper, Dr.hc.mult. MD
Center for Brain Research, Medical University of Vienna
Spitalgasse 4, 1090 Vienna, Austria

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
siegfried.kasper@meduniwien.ac.at

ABSTRACT

Theta-burst stimulation (TBS) represents a brain stimulation technique effective for treatment-resistant depression (TRD) as underlined by meta-analyses. While the methodology undergoes constant refinement, bilateral stimulation of the dorsolateral prefrontal cortex (DLPFC) appears promising to restore left DLPFC hypoactivity and right hyperactivity found in depression. The post-synaptic inhibitory serotonin-1A (5-HT_{1A}) receptor, also occurring in the DLPFC, might be involved in this mechanism of action. To test this hypothesis, we performed PET-imaging using the tracer [*carbonyl*-¹¹C]WAY-100635 including arterial blood sampling before and after a three-week treatment with TBS in 11 TRD patients compared to sham stimulation (n=8 and n=3, respectively). Treatment groups were randomly assigned, and TBS protocol consisted in excitatory intermittent TBS to the left and inhibitory continuous TBS to the right DLPFC. A linear mixed model including group, hemisphere time and Hamilton Rating Scale for Depression (HAMD) score revealed a 3-way interaction effect of group time and HAMD on 5-HT_{1A} receptor specific binding V_S. While post-hoc comparisons showed no significant changes of 5-HT_{1A} V_S in either group, higher 5-HT_{1A} V_S after treatment correlated with greater difference in HAMD (r=-0.62), indicative of potential effects of TBS on the 5-HT_{1A} receptor. Due to the small sample size, all results, however, must be regarded with caution.

KEYWORDS

Theta-burst stimulation

Transcranial magnetic stimulation

Treatment-resistant depression

Serotonin-1A receptor

Positron emission tomography

INTRODUCTION

Major depressive disorder (MDD) is a common, debilitating psychiatric illness that – along with personal suffering and psychosocial strain – represents an immense socioeconomic burden worldwide [1, 2]. MDD is a treatable disorder with pharmacological and psychotherapeutic interventions constituting the fundamental pillars of antidepressant treatment. Nevertheless, up to 60% of the patients do not satisfactorily respond to first-line pharmacological treatments [3]: This subgroup of patients is conventionally labeled as treatment-resistant, which implies the failure of response to at least two adequate antidepressant trials [4]. The significant amount of affected persons calls for an improvement of treatment outcomes by exploring alternative treatment strategies, such as novel rapid-acting antidepressants like esketamine and improved brain stimulation techniques [5-7].

Theta-burst stimulation (TBS), an enhanced derivative of repetitive transcranial magnetic stimulation (rTMS), is an effective non-pharmacological treatment option for MDD, combining the approved efficacy of rTMS while offering better practicability with significantly shorter therapy duration [8, 9]. Several double-blind, sham-controlled, multicenter trials as well as meta-analyses have provided evidence for the antidepressant effects of rTMS [10, 11], which has been approved by the United States Food and Drug Administration (FDA) as a therapeutic option for treatment-resistant depression (TRD) since 2008 [12, 13]. Since the development of this noninvasive brain stimulation technique in the 1980s [14], research into therapeutic TMS for a multitude of neurological and psychiatric disorders, particularly depression [15], has dramatically increased; its principle lies in the induction of electrical currents inside the brain by electromagnetic pulses applied on the scalp, causing neuronal depolarization and functional alteration of brain activity in specifically targeted regions.

A key variable in TMS is the application frequency of electromagnetic pulses. While low frequency or single pulses were shown to decrease brain activity in the stimulated region [16], high frequency pulses exhibit excitatory properties e.g., the FDA-approved 10-Hz or

high-frequency (HF) TMS over the left dorsolateral prefrontal cortex (DLFPC) in depression [17]. Similarly, two protocols of TBS with opposing effects on cortical excitability have been proposed; intermittent (iTBS) and continuous TBS (cTBS) with excitatory and inhibitory consequences, respectively. Bilateral TBS, which combines iTBS to the left, alleged hypoactive DLPFC and cTBS to the right, alleged hyperactive DLPFC holds promise to be the most efficacious neuromodulation measure in TRD, thereby even challenging the panacea electroconvulsive therapy (ECT) [18, 19].

Though the exact neurobiological mechanisms by which TMS alters mood remain to be elucidated, the commonly acknowledged explanation involves therapeutic neuroplasticity through long-lasting modulation of cortical excitability that go beyond the stimulated brain region [20-22]. To investigate the TMS-induced changes in neural activity patterns, several neuroimaging studies have been performed to identify brain networks involved in its antidepressant effects and inform personalized approaches in the future [23-26]. The vast majority of the trials using positron emission tomography (PET) focused on measures of cerebral blood flow [27-30] and cerebral glucose metabolism [31], showing changes in neural network dynamics beyond the cortical site directly targeted by the electromagnetic pulse. Regarding effects on modulatory neurotransmitter systems, rTMS was shown to be accompanied by increases in extracellular dopamine in the stimulated hemisphere (basal ganglia, anterior cingulate and medial orbitofrontal cortex) measured using [^{11}C]raclopride [32-34], significant changes in regional serotonin synthesis capacity in limbic areas assessed using alpha- ^{11}C -methyltryptophan [35] as well as a serum serotonin level enhancement [36]. Preclinical investigations in rats indicate that TMS might exert its antidepressant effects via modulation of the serotonergic system [37, 38], particularly the inhibitory serotonin-1A (5-HT_{1A}) [38-41]. This receptor is prone to profound changes in mood and anxiety disorders [42-45] and represents an important player of antidepressant pharmacotherapy and electroconvulsive therapy in humans as shown previously by our group [46-49]. Based on this evidence, we aimed at assessing the impact of bilateral TBS on 5-HT_{1A} receptor

distribution volume in a sample of TRD patients using the radioligand [*carbonyl*-¹¹C]WAY-100635 to probe the hypothesis of a 5-HT_{1A} receptor reduction in the DLFPC – as seen with other antidepressant treatments – by this non-invasive brain stimulation technique *in vivo*.

MATERIAL and METHODS

Subjects and study design

35 subjects suffering from treatment-resistant depression (defined as failure to respond for the current episode to two adequate medication trials of at least 4 weeks in sufficient dosage) were recruited via the outpatient department and the hospital wards of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria, and enrolled in the study (ClinicalTrials.gov Identifier NCT02810717). 24 subjects dropped out of the study, mainly due to technical and schedule planning issues, leaving a final sample size of 11. In this randomized and double-blind clinical trial patients received either bilateral Theta-burst (TBS, n=8) or sham (n=3) stimulation. Each participant underwent PET measurement with [*carbonyl*-¹¹C]WAY-100635 once before (PET1) and once after TBS treatment (PET2). In addition, structural images were recorded using magnetic resonance imaging (MRI) scans at each PET scanning session, which were used for Neuronavigation and co-registration of dynamic PET data.

Subjects were carefully screened by a psychiatrist and included in the trial when fulfilling criteria for a single or recurrent major depression (using the Structural Clinical Interview for DSM IV Diagnosis, SCID IV) and a 17-item Hamilton Rating Scale for Depression (HAM-D) score ≥ 18 (at least moderate depression) assessed at the inclusion as well as on the individual measurement days. Concomitant antidepressant treatment was allowed, if stable, four weeks prior study enrolment and during study participation. Exclusion criteria were major systemic (untreated) or neurological disorders, including brain injuries, current substance abuse (ruled out using SCID IV and a urine drug screening), current psychotic symptoms, pregnancy and any contraindication for magnetic resonance imaging or TMS [50]. Also, intake within four weeks prior the first examination visit or current intake of psychotropic drugs targeting the 5-HT_{1A} receptor (i.e. clozapine, aripiprazole, quetiapine (>100 mg), ziprasidone, amitriptyline, nebivolol, propranolol, mirtazapine, triptans, trazodone) was considered as an exclusion criterion. A causal relationship of mood disturbances and general

medical conditions was further ruled out by clinical examination, routine laboratory measurements (complete blood cell count, chemistry, thyroid hormones) and an electrocardiogram.

Study data were collected and managed using REDCap electronic data capture tools hosted at the Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria [51, 52]. The study was approved by the ethics committee of the Medical University of Vienna, Austria (1761/2015). Each subject provided written informed consent and was financially reimbursed for the participation in the study. Procedures performed during the study were in accordance with the Declaration of Helsinki including all revisions.

Theta-burst stimulation treatment

Patients were treated with bilateral TBS or sham TBS using MagPro X100 model (MagVenture, Tonica Elektronik A/S, Denmark, www.tonika.dk) and a Cool-B70 Butterfly coil. For each treatment session intermittent TBS (iTBS) was applied to the left dorsolateral prefrontal cortex (DLPFC), whereas continuous TBS (cTBS) was applied to the right DLPFC at an intensity of 120% resting motor threshold for the first dorsal interosseous muscle [53]. The iTBS consisted of 2-second trains with an inter-train-interval of 8 seconds. Trains (30 pulses, 10 bursts) were repeated 20 times to reach a total number of 600 pulses per session. The cTBS comprised uninterrupted bursts reaching a total number of 600 pulses per session. For both iTBS and cTBS 3-pulse 50-Hz bursts were given every 200 ms [9]. Two sessions, each lasting ~5 minutes, were scheduled daily, given 60 minutes apart [54], Monday to Friday, for three weeks resulting in a minimum of 30 sessions per subjects. Coil placement to the left and right DLPFC was performed using neuro-navigation (Brainsight, LOCALITE® TMS Navigator, Germany [55]) based on MNI coordinates $x=\pm 38$, $y=44$, $z=26$ from individual MR images. Sham TBS comprised bursts as given above with the coil set at 90° against the skull. Thus, sham stimulation was accompanied by similar auditory (clicking noise) and somatosensory (i.e. pricking) artefacts. Patients were blind to the individual group

assignment. Efficacy outcome measures were assessed by blinded raters, who were not permitted access to the treatment sessions.

Neuroimaging

Each PET scan was conducted using a GE Advance PET scanner (General Electric Medical Systems, Milwaukee, Wisconsin) at the Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria as previously described [48, 49, 56, 57]. To correct for tissue attenuation, 5-minute transmission scan was carried in 2-D mode (retractable ^{68}Ge rod sources). Afterwards, PET measurement started with the bolus administration of [*carbonyl*- ^{11}C]WAY-100635 (injection dose 4.6 MBq/kg body weight) in cubital vein. All scans were acquired in 3-D mode for 90 minutes (51 frames: 12x5 s, 6x10 s, 3x20 s, 6x30 s, 9x60 s, 15x300 s) and were reconstructed (iterative filtered back-projection algorithm) to final images comprising a spatial resolution of 4.36mm full-width at half-maximum 1 cm next to the center of the field of view (matrix 128x128, 35 slices). The radioligand [*carbonyl*- ^{11}C]WAY-100635 was prepared according to previously published methods [58] at the Cyclotron Unit of the PET Center.

Each PET scan was complemented with arterial blood samples for the quantification of [*carbonyl*- ^{11}C]WAY-100635 that were automatically drawn for first 10 minutes (ALLOGG, Mariefred, Sweden) and manually at 2, 5, 6, 7, 8, 10, 20, 40 and 60 minute of the measurement.

Structural T1 weighted MR image were acquired at both PET measurements with the magnetization prepared rapid gradient echo sequence (MP-RAGE with TE/TR = 4.21/3000 ms, voxel size $1 \times 1 \times 1.1 \text{ mm}^3$) using a 3 T PRISMA MR Scanner (Siemens Medical, Erlangen, Germany).

Data processing and quantification

Following correction for tissue attenuation, PET scan of each patient was corrected for head motion, co-registered to the structural T1-weighted image. The latter was afterwards

normalized to MNI space producing a transformation matrix that was further applied to normalize co-registered PET data to MNI space. All preprocessing steps were done using SPM (Wellcome Trust Centre for Neuroimaging, London, United Kingdom; <http://www.fil.ion.ucl.ac.uk/spm/>) and Matlab 2018a (The Mathworks Inc., Natick, MA, USA). Subsequently, time activity curves (TACs) were extracted for selected regions of interest (ROIs) - left and right DLPFC and cerebellar white matter (CWM). DLPFC ROIs were defined as a sphere with diameter of 10 mm around the MNI coordinate representing the individual application point of TBS treatment. The CWM ROI was extracted using an in-house created atlas [59]. To reduce the noise induced by short frames in the beginning of the scan, the first 2 minutes (frames 12x5 s and 6x10 s) of the measurement were resampled to 20-second frames.

The arterial input functions representing non-metabolized radioligand in plasma were obtained as product of the whole blood activity, plasma-to-whole blood ratio (average) and fraction of intact radioligand in the plasma (fitted with the Hill-type function). Afterwards, the distribution volume of specifically bound ligand V_S , representing the distribution of 5-HT_{1A} receptor, was estimated for DLPFC. Quantification of 5-HT_{1A} V_S was carried out utilizing a constrained 2 two-tissue compartment model. Here, CWM was fitted and the ratio of K_1/k_2 was fixed for the DLPFC regions [60].

Statistical analysis

All statistical analyses were performed in SPSS version 28 for Windows (SPSS Inc., Chicago, Illinois; www.spss.com). A linear mixed model was used to assess the effect of TBS treatment on 5-HT_{1A} receptor V_S in the DLPFC in TRD patients using group assignment (TBS or sham), time point of measurement (PET 1 or PET 2) and hemisphere of ROI as fixed factors and HAMD scores, representing a scale predictor, as covariate. Of note, the factor hemisphere was introduced in the statistical model as iTBS and cTBS to the left and right

DLPFC, respectively, are presumed to display opposing effects on brain activation, thereby potentially bearing lateralized effects on 5-HT_{1A} receptor distribution.

The Mann-Whitney U-test was utilized to assess possible difference in the baseline HAMD score between both groups. Post-hoc exploratory tests for the interactions were done using Wilcoxon Signed Ranked Test. The relationship between V_S and HAMD was investigated using the Spearman's Rank correlation via change in HAMD ($\Delta HAMD = HAMD_{PET2} - HAMD_{PET1}$) and the change in V_S ($\Delta V_S = V_{S_{PET2}} - V_{S_{PET1}}$) for the verum group.

In addition, lateralization quotient describing the difference between the activation in left and right hemisphere (LQ [61]) was calculated for each time point (PET1 and PET2) for TBS group for DLPFC (see Table 2).

$$LQ[\%] = \frac{V_{S_left} - V_{S_right}}{V_{S_left} + V_{S_right}} \times 100$$

Afterwards, a Wilcoxon Signed Ranks Test was used for possible changes in LQ between PET 1 and PET 2. All statistical tests were assessed on the significance level 0.05. No further corrections for multiple testing were done, as the analysis is of exploratory nature.

RESULTS

Data from eleven TRD subjects were available to examine the impact of three weeks of TBS on 5-HT_{1A} V_S in the left and right DLPFC. The sample's demographics are summarized in Table 1. Eight subjects (five women) aged 35.9 ± 8.4 received i/cTBS, three subjects (only women) aged 40.3 ± 8.0 received sham stimulation. Mean baseline HAMD scores were 18.5 ± 3.6 and 22.0 ± 2.7 , respectively, and comparable in both groups (Mann Whitney U test, $p=0.18$). Concomitant medication of the participants is subsumed in the supplementary Table.

Group	TBS	Sham
n	8 (5 female)	3 (3 female)
age	35.88 ± 8.41	40.33 ± 6.03
baseline HAMD (PET 1)	18.50 ± 3.55	22.00 ± 2.65
HAMD after treatment (PET 2)	12.12 ± 5.44	17.33 ± 10.02
number of responders	2	1

Table 1 Demographic information about the patients included in the study.

Response to treatment was defined as a reduction of baseline HAMD $\geq 50\%$. 2 out of 8 (25%) TBS-treated subjects fulfilled these criteria at PET 2 (after TBS), 1 out of 3 (33%) in the sham group.

Linear mixed model analysis using group (TBS vs. sham), time (PET 1 vs. PET 2), hemisphere (left vs. right) and HAMD score showed a main effect of group ($F=6.75$, $p=0.019$), time ($F=7.45$, $p=0.015$) and HAMD ($F=11.00$, $p=0.004$) on 5-HT_{1A} V_S as well as two-way interactions between group*time ($F=6.24$, $p=0.024$), time*HAMD ($F=7.30$, $p=0.015$), group*HAMD ($F=6.10$, $p=0.025$), and a three-way interaction between group*time*HAMD ($F=6.02$, $p=0.025$). All other two- or three-way interactions and the main effect of hemisphere were non-significant. Post-hoc comparisons using Wilcoxon Signed Ranks test revealed no

significant changes of 5-HT_{1A} V_S at PET 2 compared to PET 1 in the TBS ($p=0.67$) and sham group ($p=1.00$). The estimates of 5-HT_{1A} V_S (averaged over hemispheres) were 3.21 ± 1.40 at PET 1 and 3.42 ± 0.80 at PET2 in the TBS group, and 3.13 ± 2.05 at PET 1 and 3.46 ± 0.52 at PET 2 in sham group (see Figure 1).

Figure 1 Average 5-HT_{1A} V_S in DLPFC for TBS and Sham group at both measurement time points

Spearman's rank correlation between change of 5-HT_{1A} V_S and Δ HAMD between both PET measurements revealed a negative correlation in the TBS group ($r=-0.62$, $p=0.999$) (see Figure 2). Due to the small sample size, this correlation is not reported for the sham group ($n=3$).

Relation between the change in specific binding (Vs) in DLPFC and HAM-D scores in TBS group

Figure 2 Scatter plot showing the relationship between the Δ HAMD score and ΔV_s between PET1 and PET2 in the TBS group. Spearman's rank correlation showed $r=-0.66$ ($p=0.099$).

LQ was computed separately for each group (see Table 2) and did not change following treatment in the TBS group (Wilcoxon Signed Rank test, $p=0.069$). Due to the small sample size, we did not perform this test in the sham group ($n=3$).

Group	TBS	Sham
LQ PET 1	15.58 $\pm$ 3.55	3.28 $\pm$ 6.52
LQ PET 2	-2.13 $\pm$ 7.68	-6.10 $\pm$ 7.71

Table 2 Average lateralization quotient of V_s was calculated for each time point and each group separately

DISCUSSION

Specific distribution volumes of 5-HT_{1A} in the stimulation epicenters located in the left and right DLPFC as assessed using [*carbonyl*-¹¹C]WAY-100635 appeared to be differentially affected by three weeks of bilateral TBS treatment (iTBS over the left and cTBS over the right DLPFC) compared to sham stimulation in a sample of eleven TRD patients. Given the small sample size particularly in the sham group, the results of this longitudinal PET study should be considered exploratory and must therefore be interpreted carefully.

Based on earlier imaging findings published by our group using the same radioligand (see below), we expected a reduction of 5-HT_{1A} V_S in the target region upon completion of TBS. In fact, a reduced availability of 5-HT_{1A} receptors might represent a common neural ground for pharmacological and non-pharmacological antidepressant treatments. Three months of escitalopram intake in patients with anxiety disorders were accompanied by significant reductions in binding potentials in limbic regions [47]. The same direction of change was shown in the raphe in a medication-free depressed sample after SSRI treatment [62]. Interestingly, reductions of 5-HT_{1A} receptor binding were also observed in cortical brain regions following eight weeks of daily intake of Silexan[®], an anxiolytic herbal compound of lavender essential oil [49]. Most pronounced and widespread cortical reductions of 5-HT_{1A} receptor binding (~30%) were reported following a course of ECT [48]. However, in none of the studies mentioned above was the degree of binding reductions over time correlated with treatment outcomes.

In the present study, though post-hoc tests did not reveal significant differences in 5-HT_{1A} V_S between both PET scans, absolute numbers indicate a slight and unexpected increase of outcome measures in the stimulation epicenters located in the DLPFC in both groups. In addition, the Spearman's rank correlation between the change of 5-HT_{1A} V_S and HAMD after the treatment course suggests the greater the increase of V_S after the treatment course, the greater the reduction of HAMD scores (and the greater the response). Since we did not find

significant differences between hemispheres, left iTBS and right cTBS seem to similarly affect the distribution of the 5-HT_{1A} receptor. Given the general assumption that activation of 5-HT_{1A} receptors in projection areas mediates a hyperpolarizing response to serotonin on pyramidal neurons and GABA-ergic neurons [63], an increase of 5-HT_{1A} availability in the DLPFC might result in a disinhibition of neurotransmission and increase in neuronal activity. Though highly speculative, in theory, this constitutes the desired effect of iTBS to the left DLPFC in depression [18]. Currently, no previous *in vivo* data exists to explain our results; however, novel cellular models might be promising to test this hypothesis [64]. Contrasting results regarding 5-HT_{1A} receptor binding might arise through differences in the methodology used, including the choice of reference region and modeling [65, 66].

Still, there is a high level of preclinical evidence supporting our hypothesis of TMS-induced changes within the serotonergic system. Several animal studies have indicated that rTMS may affect the serotonergic system through the 5-HT_{1A} receptors, the most important inhibitory receptor subtype within the serotonergic receptor family, either expressed as an autoreceptor on presynaptic serotonergic neurons or as a heteroreceptor on postsynaptic neurons in projection sites [45]. Single rapid-rate rTMS exposure led to significant increases in 5-HT_{1A} receptors in the frontal cortex as quantified by in-vitro autoradiography 24h after the intervention in rats [38]. Chronic rTMS reduced the ability of OH-DPAT, a full 5-HT_{1A} receptor agonist, to decrease serotonin levels in projection sites, which is indicative of a reduced sensitivity of 5-HT_{1A} autoreceptors [40]. Investigations using intracerebral microdialysis indicate the selective release of monoamines following rTMS, however not necessarily of serotonin [38, 67, 68]. Only few reports show an rTMS-induced serotonin level increase in the rat hippocampus [37, 69] and nucleus accumbens [70], an effect that was also reported in humans [36]. In contrast to the 5-HT_{1A} receptor, the major excitatory serotonin receptor 5-HT_{2A} was shown to be downregulated by chronic rTMS in rats [71]; interestingly, in humans, decrease of 5-HT_{2A} receptors in the hippocampus and the bilateral DLPFC was correlated with treatment response to HF rTMS [72]. Finally, evidence retrieved

from genetic investigations emphasizes the association of the 5-HT_{1A} receptor and TMS, as the genotype of the 5-HT_{1A} receptor promoter region polymorphism (rs6295) was shown to influence the outcome of HF TMS in patients suffering from a major depressive episode [73, 74]. It has been suggested that a greater load of G alleles in a 5-HT_{1A} receptor promoter polymorphism might be associated with lower serotonin release, resulting in a post-synaptic upregulation of the 5-HT_{1A} receptor [65]. This polymorphism was, however, not assessed in our study sample.

The effect of TMS in TRD is frequently associated with plastic changes affecting synapse formation, long-term potentiation (LTP) and depression (LTD) [75, 76]. In a study in mice, Cambiaghi et al. have shown, for example, that high frequency rTMS leads to an increase in dendritic complexity in layer II/III pyramidal neurons of the primary motor cortex [77]. The 5-HT_{1A} receptor, in combination with 5-HT signaling, has been repeatedly implicated in plastic changes, including alterations in gray matter volumes [78, 79]. Since the receptor is also located on pyramidal neurons in layers III [80], rTMS might influence its expression and thus mediate its effect on synaptogenesis. Of note, rTMS of glial cells affects neuronal excitability and might, through the presence of 5-HT_{1A} receptors on glial cells [81], lead to alterations in 5-HT_{1A} availability and thus contribute to neuroplasticity [82]. Data on the interplay of rTMS and 5-HT_{1A} receptors in pyramidal and glial cells in cell cultures is however missing up until now [81].

According to the chosen treatment protocol in this study, applying (excitatory) iTBS to the left DLPFC and (inhibiting) cTBS to the right DLPFC, we would have expected a clearer change in LQ between PET 1 and PET 2 in the TBS group. However, the latter was not significant. Considering the absolute values of the computed index, the LQ was positive at baseline in both groups, implying a higher 5-HT_{1A} receptor binding on the left compared to the right hemisphere in symptomatic, depressed patients, and negative following three weeks of treatment, corresponding to a 5-HT_{1A} distribution reversal that seems more pronounced in

the TBS group. This is in accordance with the presumed left and right hemispheric divergence of metabolism and neuronal activation in depression [83, 84] suggesting that our results might have shown clearer trends in the TBS group in a larger sample [85].

Regarding clinical data of our population, the HAM-D scores at baseline in both the verum and sham groups were somewhat lower than in other studies investigating TMS in TRD [54, 86, 87], but are still reflective of an at least moderate depressive episode. The response rates were 25% in the verum group (2 out of 8), and 33.3% in the sham group (1 out of 3). While these rates seem to differ from recent studies by Berlim et al. and Voigt et al. [19, 88], a meta-analysis of Lepping et al. also finds high sham response rates [89]. The technology of transcranial magnetic stimulation undergoes constant refinement, hence studies on effects of TMS show great heterogeneity in treatment protocols (and duration) and inclusion criteria. Of note, in the current study recruitment was limited to patients currently not receiving treatment with mirtazapine, trazodone, quetiapine, aripiprazole, compatible for PET imaging of the 5-HT_{1A} receptor, as well as patients not receiving antiepileptic drugs or benzodiazepines on a regular basis regarding TBS treatment. Also, trajectories of remission and response to TMS seem to depend on specific characteristics, including age, benzodiazepine use and baseline depression severity [90]. An adequate level of functioning represents one condition for TBS, particularly in an outpatient setting, allowing for the inclusion of less severely depressed TRD patients (in comparison to, for example electroconvulsive therapy [91]). In addition, daily sessions might provide for a certain level of activation that could influence depression scores and symptom improvement over the treatment course. While treatment protocols for TBS are continuously refined based on new evidence, the herein reported response rates must be considered with caution, especially with our comparatively small sham group.

The size of the sham group (comprising female subjects only), but also the general sample size of 11 subjects constitutes the most important limitation of this study, restricting the generalizability of our data [92]. To increase statistical sensitivity, we focused our analysis on

the bilateral DLPFCs where TBS was administered. However, other ROIs, especially the raphe, but also the hippocampus and amygdala, where changes in 5-HT_{1A} receptor might be expected, are missing in this analysis. Also, we did not account for potential effects of concomitant antidepressant pharmacotherapy in our analyses [93]. Given that treatment regimens had to remain unchanged throughout study participation, we expect these to be negligible.

In conclusion, we could show an effect of three-week bilateral TBS treatment on the distribution volumes of the 5-HT_{1A} receptor in a group of patients suffering from treatment resistant depression, with an increase in 5-HT_{1A} receptor availability correlating with a greater difference in depression score post-treatment. While these results appear indicative for a connection of the 5-HT_{1A} receptor with the mechanisms of action of theta-burst stimulation, they must be interpreted with caution, particularly because of the small sample and sham group size.

ACKNOWLEDGEMENTS

This research was funded in whole, or in part, by the Austrian Science Fund (FWF) [Grant number KLI 551, PI: S. Kasper]. M. Murgaš is funded by the Austrian Science Fund (FWF) [Grant number DOC 33-B27, Supervisor R. Lanzenberger]. M.B. Reed is a recipient of a DOC fellowship of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna. We would like to express our gratitude towards Jonathan Downar for his assistance in the conceptualization of the study. We would further like to thank Gregor Gryglewski, Marius Hienert, Marie Spies, Christoph Kraus, Alexander Kautzky, Arkadiusz Komorowski, Paul Michenthaler, and Richard Frey for clinical support, and Lucas Rischka and Sebastian Ganger for technical support, and all additional staff and students from the Neuroimaging Lab (NIL) involved in the realization of this research. Moreover, we would like to thank radiotechnologists, Ingrid Leitinger and Harald Ibeschitz, for operating PET.

CONFLICT OF INTEREST

In the past three years S. Kasper has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speaker bureaus for Abbott, Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Lundbeck, Recordati, Sage, Sanofi, Schwabe, Servier, Sun Pharma and Vifor. Without any relevance to this work, R. Lanzenberger declares that he received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and Heel, and has served as a consultant for Ono Pharmaceutical. He received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. G.S. Kranz declares that he received conference speaker honorarium from Roche, AOP Orphan and Pfizer. T. Vanicek has served on speaker bureaus for Jansen. Without relevance to this work, W. Wadsak received within the last 3 years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics

(Fürstenfeldbruck, Germany). He is a part-time employee of CBmed GmbH (Graz, Austria) and a co-founder of MINUTE medical GmbH (Vienna, Austria). Without relevance to this work, M. Mitterhauser is scientific advisor for ROTOP Pharma GmbH. The other authors do not report any conflict of interest.

REFERENCES

- [1] Rehm J, Shield KD. Global Burden of Disease and the Impact of Mental and Addictive Disorders. *Current psychiatry reports* 2019;21(2):10.
- [2] Smith K. Trillion-dollar brain drain. *Nature* 2011;478(7367):15-.
- [3] Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, et al. Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2019;20(6):427-48.
- [4] Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. *International journal of psychiatry in clinical practice* 2017;21(1):13-23.
- [5] Kraus C, Kadriu B, Lanzenberger R, Zarate CA, Jr., Kasper S. Prognosis and improved outcomes in major depression: a review. *Translational psychiatry* 2019;9(1):127.
- [6] Kasper S, Cubala WJ, Fagiolini A, Ramos-Quiroga JA, Souery D, Young AH. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2021;22(6):468-82.
- [7] Blumberger DM, Mulsant BH, Daskalakis ZJ. What is the role of brain stimulation therapies in the treatment of depression? *Current psychiatry reports* 2013;15(7):368.
- [8] Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *Lancet (London, England)* 2018;391(10131):1683-92.
- [9] Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. *Neuron* 2005;45(2):201-6.
- [10] Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology* 2020;131(2):474-528.
- [11] Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. *Psychological medicine* 2014;44(2):225-39.
- [12] O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biological psychiatry* 2007;62(11):1208-16.
- [13] George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. *Archives of general psychiatry* 2010;67(5):507-16.
- [14] Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. *Lancet (London, England)* 1985;1(8437):1106-7.
- [15] Höflich G, Kasper S, Hufnagel A, Ruhrmann S, Möller H-J. Application of transcranial magnetic stimulation in treatment of drug-resistant major depression—a report of two cases. *Human Psychopharmacology: Clinical and Experimental* 1993;8(5):361-5.
- [16] Casula EP, Tarantino V, Basso D, Arcara G, Marino G, Toffolo GM, et al. Low-frequency rTMS inhibitory effects in the primary motor cortex: Insights from TMS-evoked potentials. *NeuroImage* 2014;98:225-32.
- [17] Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic

stimulation (rTMS). *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology* 2014;125(11):2150-206.

- [18] Li H, Cui L, Li J, Liu Y, Chen Y. Comparative efficacy and acceptability of neuromodulation procedures in the treatment of treatment-resistant depression: a network meta-analysis of randomized controlled trials. *Journal of affective disorders* 2021;287:115-24.
- [19] Berlim MT, McGirr A, Rodrigues Dos Santos N, Tremblay S, Martins R. Efficacy of theta burst stimulation (TBS) for major depression: An exploratory meta-analysis of randomized and sham-controlled trials. *Journal of psychiatric research* 2017;90:102-9.
- [20] Lazzaro VD, Ziemann U, Lemon RN. State of the art: Physiology of transcranial motor cortex stimulation. *Brain Stimulation* 2008;1(4):345-62.
- [21] Ilić TV, Ziemann U. Exploring motor cortical plasticity using transcranial magnetic stimulation in humans. *Annals of the New York Academy of Sciences* 2005;1048:175-84.
- [22] Ziemann U, Ilić TV, Jung P. Long-term potentiation (LTP)-like plasticity and learning in human motor cortex--investigations with transcranial magnetic stimulation (TMS). *Supplements to Clinical neurophysiology* 2006;59:19-25.
- [23] Reithler J, Peters JC, Sack AT. Multimodal transcranial magnetic stimulation: using concurrent neuroimaging to reveal the neural network dynamics of noninvasive brain stimulation. *Progress in neurobiology* 2011;94(2):149-65.
- [24] Garnaat SL, Fukuda AM, Yuan S, Carpenter LL. Identification of Clinical Features and Biomarkers that may inform a Personalized Approach to rTMS for Depression. *Personalized medicine in psychiatry* 2019;17-18:4-16.
- [25] Hernández-Ribas R, Deus J, Pujol J, Segalàs C, Vallejo J, Menchón JM, et al. Identifying brain imaging correlates of clinical response to repetitive transcranial magnetic stimulation (rTMS) in major depression. *Brain Stimul* 2013;6(1):54-61.
- [26] Fidalgo TM, Morales-Quezada JL, Muzy GS, Chiavetta NM, Mendonca ME, Santana MV, et al. Biological markers in noninvasive brain stimulation trials in major depressive disorder: a systematic review. *The journal of ECT* 2014;30(1):47-61.
- [27] Paus T, Castro-Alamancos MA, Petrides M. Cortico-cortical connectivity of the human mid-dorsolateral frontal cortex and its modulation by repetitive transcranial magnetic stimulation. *The European journal of neuroscience* 2001;14(8):1405-11.
- [28] Knoch D, Treyer V, Regard M, Müri RM, Buck A, Weber B. Lateralized and frequency-dependent effects of prefrontal rTMS on regional cerebral blood flow. *NeuroImage* 2006;31(2):641-8.
- [29] Speer AM, Willis MW, Herscovitch P, Daube-Witherspoon M, Shelton JR, Benson BE, et al. Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with H215O positron emission tomography: II. Effects of prefrontal cortex rTMS. *Biological psychiatry* 2003;54(8):826-32.
- [30] Ferrarelli F, Haraldsson HM, Barnhart TE, Roberts AD, Oakes TR, Massimini M, et al. A [17F]-fluoromethane PET/TMS study of effective connectivity. *Brain research bulletin* 2004;64(2):103-13.
- [31] Kimbrell TA, Dunn RT, George MS, Danielson AL, Willis MW, Repella JD, et al. Left prefrontal-repetitive transcranial magnetic stimulation (rTMS) and regional cerebral glucose metabolism in normal volunteers. *Psychiatry research* 2002;115(3):101-13.
- [32] Ko JH, Monchi O, Pito A, Bloomfield P, Houle S, Strafella AP. Theta burst stimulation-induced inhibition of dorsolateral prefrontal cortex reveals hemispheric asymmetry in striatal dopamine release during a set-shifting task: a TMS-[(11)C]raclopride PET study. *The European journal of neuroscience* 2008;28(10):2147-55.
- [33] Strafella AP, Paus T, Fraraccio M, Dagher A. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. *Brain : a journal of neurology* 2003;126(Pt 12):2609-15.

- [34] Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2001;21(15):Rc157.
- [35] Sibon I, Strafella AP, Gravel P, Ko JH, Booij L, Soucy JP, et al. Acute prefrontal cortex TMS in healthy volunteers: effects on brain 11C-alphaMtrp trapping. *NeuroImage* 2007;34(4):1658-64.
- [36] Lu R, Zhang C, Liu Y, Wang L, Chen X, Zhou X. The effect of bilateral low-frequency rTMS over dorsolateral prefrontal cortex on serum brain-derived neurotrophic factor and serotonin in patients with generalized anxiety disorder. *Neuroscience letters* 2018;684:67-71.
- [37] Ben-Shachar D, Belmaker RH, Grisaru N, Klein E. Transcranial magnetic stimulation induces alterations in brain monoamines. *Journal of neural transmission (Vienna, Austria : 1996)* 1997;104(2-3):191-7.
- [38] Kole MH, Fuchs E, Ziemann U, Paulus W, Ebert U. Changes in 5-HT1A and NMDA binding sites by a single rapid transcranial magnetic stimulation procedure in rats. *Brain research* 1999;826(2):309-12.
- [39] Pollandt S, Drephal C, Albrecht D. 8-OH-DPAT suppresses the induction of LTP in brain slices of the rat lateral amygdala. *Neuroreport* 2003;14(6):895-7.
- [40] Gur E, Lerer B, Dremencov E, Newman ME. Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. *Neuroreport* 2000;11(13):2925-9.
- [41] Johnson MT, McCullough J, Nindl G, Chamberlain JK. Autoradiographic evaluation of electromagnetic field effects on serotonin (5HT1A) receptors in rat brain. *Biomedical sciences instrumentation* 2003;39:466-70.
- [42] Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. *Biological psychiatry* 2007;61(9):1081-9.
- [43] Nugent AC, Bain EE, Carlson PJ, Neumeister A, Bonne O, Carson RE, et al. Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2013;23(8):822-9.
- [44] Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced serotonin type 1A receptor binding in panic disorder. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2004;24(3):589-91.
- [45] Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. *Progress in neurobiology* 2009;88(1):17-31.
- [46] Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, et al. Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. *Molecular psychiatry* 2013;18(1):1.
- [47] Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M, et al. Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. *Molecular psychiatry* 2009;14(11):1040-50.
- [48] Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, et al. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. *Molecular psychiatry* 2013;18(1):93-100.
- [49] Baldinger P, Höflich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, et al. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. *The international journal of neuropsychopharmacology* 2014;18(4).

- [50] Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Screening questionnaire before TMS: an update. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology* 2011;122(8):1686.
- [51] Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *Journal of biomedical informatics* 2019;95:103208.
- [52] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of biomedical informatics* 2009;42(2):377-81.
- [53] Ge R, Blumberger DM, Downar J, Daskalakis ZJ, Dipinto AA, Tham JCW, et al. Abnormal functional connectivity within resting-state networks is related to rTMS-based therapy effects of treatment resistant depression: A pilot study. *Journal of affective disorders* 2017;218:75-81.
- [54] Li CT, Chen MH, Juan CH, Huang HH, Chen LF, Hsieh JC, et al. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. *Brain : a journal of neurology* 2014;137(Pt 7):2088-98.
- [55] Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. *Biological psychiatry* 2012;72(7):595-603.
- [56] Hahn A, Nics L, Baldinger P, Ungersböck J, Dolliner P, Frey R, et al. Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. *NeuroImage* 2012;62(1):199-206.
- [57] Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien L-K, et al. Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. *Biological psychiatry* 2007;61(9):1081-9.
- [58] Wadsak W, Mien L-K, Ettlinger DE, Eidherr H, Haeusler D, Sindelar K-M, et al. 18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers. *Nuclear Medicine and Biology* 2007;34(8):1019-28.
- [59] Savli M, Bauer A, Mitterhauser M, Ding Y-S, Hahn A, Kroll T, et al. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. *NeuroImage* 2012;63(1):447-59.
- [60] Parsey RV, Slifstein M, Hwang D-R, Abi-Dargham A, Simpson N, Mawlawi O, et al. Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions. *Journal of Cerebral Blood Flow & Metabolism* 2000;20(7):1111-33.
- [61] Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, et al. Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. *NeuroImage* 2009;45(2):598-605.
- [62] Gray NA, Milak MS, DeLorenzo C, Ogden RT, Huang YY, Mann JJ, et al. Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. *Biological psychiatry* 2013;74(1):26-31.
- [63] Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. 5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. *Psychopharmacology* 2014;231(4):623-36.
- [64] Aberra AS, Wang B, Grill WM, Peterchev AV. Simulation of transcranial magnetic stimulation in head model with morphologically-realistic cortical neurons. *Brain Stimul* 2020;13(1):175-89.

- [65] Parsey RV, Ogden RT, Miller JM, Tin A, Hesselgrave N, Goldstein E, et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. *Biological psychiatry* 2010;68(2):170-8.
- [66] Hahn A, Nics L, Baldinger P, Wadsak W, Savli M, Kraus C, et al. Application of image-derived and venous input functions in major depression using [carbonyl-(11)C]WAY-100635. *Nucl Med Biol* 2013;40(3):371-7.
- [67] Keck ME, Sillaber I, Ebner K, Welt T, Toschi N, Kaehler ST, et al. Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain. *The European journal of neuroscience* 2000;12(10):3713-20.
- [68] Kanno M, Matsumoto M, Togashi H, Yoshioka M, Mano Y. Effects of acute repetitive transcranial magnetic stimulation on dopamine release in the rat dorsolateral striatum. *Journal of the neurological sciences* 2004;217(1):73-81.
- [69] Juckel G, Mendlin A, Jacobs BL. Electrical stimulation of rat medial prefrontal cortex enhances forebrain serotonin output: implications for electroconvulsive therapy and transcranial magnetic stimulation in depression. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 1999;21(3):391-8.
- [70] Löffler S, Gasca F, Richter L, Leipscher U, Trillenberg P, Moser A. The effect of repetitive transcranial magnetic stimulation on monoamine outflow in the nucleus accumbens shell in freely moving rats. *Neuropharmacology* 2012;63(5):898-904.
- [71] Ben-Shachar D, Gazawi H, Riboyad-Levin J, Klein E. Chronic repetitive transcranial magnetic stimulation alters beta-adrenergic and 5-HT₂ receptor characteristics in rat brain. *Brain research* 1999;816(1):78-83.
- [72] Baeken C, De Raedt R, Bossuyt A, Van Hove C, Mertens J, Dobbeleir A, et al. The impact of HF-rTMS treatment on serotonin(2A) receptors in unipolar melancholic depression. *Brain Stimul* 2011;4(2):104-11.
- [73] Malaguti A, Rossini D, Lucca A, Magri L, Lorenzi C, Pirovano A, et al. Role of COMT, 5-HT(1A) , and SERT genetic polymorphisms on antidepressant response to Transcranial Magnetic Stimulation. *Depression and anxiety* 2011;28(7):568-73.
- [74] Zanardi R, Magri L, Rossini D, Malaguti A, Giordani S, Lorenzi C, et al. Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2007;17(10):651-7.
- [75] Hoogendam JM, Ramakers GM, Di Lazzaro V. Physiology of repetitive transcranial magnetic stimulation of the human brain. *Brain Stimul* 2010;3(2):95-118.
- [76] Huang YZ, Rothwell JC, Chen RS, Lu CS, Chuang WL. The theoretical model of theta burst form of repetitive transcranial magnetic stimulation. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology* 2011;122(5):1011-8.
- [77] Cambiaghi M, Cherchi L, Masin L, Infortuna C, Briski N, Caviasco C, et al. High-frequency repetitive transcranial magnetic stimulation enhances layer II/III morphological dendritic plasticity in mouse primary motor cortex. *Behavioural brain research* 2021;410:113352.
- [78] Zanderigo F, Pantazatos S, Rubin-Falcone H, Ogden RT, Chhetry BT, Sullivan G, et al. In vivo relationship between serotonin 1A receptor binding and gray matter volume in the healthy brain and in major depressive disorder. *Brain structure & function* 2018;223(6):2609-25.
- [79] Kraus C, Hahn A, Savli M, Kranz GS, Baldinger P, Höflich A, et al. Serotonin-1A receptor binding is positively associated with gray matter volume -- a multimodal neuroimaging study combining PET and structural MRI. *NeuroImage* 2012;63(3):1091-8.

- [80] Burnet PW, Eastwood SL, Harrison PJ. [3H]WAY-100635 for 5-HT_{1A} receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. *Neurochemistry international* 1997;30(6):565-74.
- [81] Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT_{1A} receptor in primate brain neurons and glial cells. *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology 1996;14(1):35-46.
- [82] Clarke D, Beros J, Bates KA, Harvey AR, Tang AD, Rodger J. Low intensity repetitive magnetic stimulation reduces expression of genes related to inflammation and calcium signalling in cultured mouse cortical astrocytes. *Brain Stimul* 2021;14(1):183-91.
- [83] Martinot JL, Hardy P, Feline A, Huret JD, Mazoyer B, Attar-Levy D, et al. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. *The American journal of psychiatry* 1990;147(10):1313-7.
- [84] Aleman A. Use of repetitive transcranial magnetic stimulation for treatment in psychiatry. *Clinical psychopharmacology and neuroscience* : the official scientific journal of the Korean College of Neuropsychopharmacology 2013;11(2):53-9.
- [85] Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. *Psychological medicine* 2009;39(1):65-75.
- [86] Li CT, Chen MH, Juan CH, Liu RS, Lin WC, Bai YM, et al. Effects of prefrontal theta-burst stimulation on brain function in treatment-resistant depression: A randomized sham-controlled neuroimaging study. *Brain Stimul* 2018;11(5):1054-62.
- [87] Plewnia C, Pasqualetti P, Große S, Schlipf S, Wasserka B, Zwissler B, et al. Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial. *Journal of affective disorders* 2014;156:219-23.
- [88] Voigt JD, Leuchter AF, Carpenter LL. Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis. *Translational psychiatry* 2021;11(1):330.
- [89] Lepping P, Schönfeldt-Lecuona C, Sambhi RS, Lanka SV, Lane S, Whittington R, et al. A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation. *Acta psychiatrica Scandinavica* 2014;130(5):326-41.
- [90] Kaster TS, Downar J, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, et al. Trajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study. *The American journal of psychiatry* 2019;176(5):367-75.
- [91] Mutz J, Vipulanathan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. *BMJ (Clinical research ed)* 2019;364:11079.
- [92] Eisenegger C, Treyer V, Fehr E, Knoch D. Time-course of "off-line" prefrontal rTMS effects--a PET study. *NeuroImage* 2008;42(1):379-84.
- [93] Choi YK, Gardner MP, Tarazi FI. Developmental effects of antipsychotic drugs on serotonin receptor subtypes. *Synapse (New York, NY)* 2017;71(10):e21988.